Coherus Oncology (CHRS) Cash Flow Statement

Click line-items for a historical chart and %

Net income/(loss)	17.77M
Depreciation and amortization	14.45M
Stock-based compensation
Accretion of discount on 1.125% Senior Convertible Notes	1.83M
Deferred income taxes	813K
Gain on repurchase of 1.125% Senior Convertible Notes
Write down of capital assets due to restructuring	0
Net (gain)/loss from disposition of capital assets	69K
Accounts receivable, net	27.8M
Merchandise inventories	-20.89M
Accounts payable	23.19M
Prepayments and other	3.55M
Accrued expenses and other	-9.68M
Net cash provided by operating activities	60.25M
Investment in capital assets	-13.13M
Proceeds from sales of capital assets	0
Proceeds from sales of securities
Increase in other assets	-24K
Net cash used by investing activities	-13.15M
Repayments of long-term borrowings	-1.39M
Repurchases of 1.125% Senior Convertible Notes
Payment of deferred financing costs
Issuance of common stock under employee stock plans, net of amounts withheld for payroll taxes	-233K
Net cash used by financing activities	-1.62M
Increase in cash and cash equivalents	45.48M
Cash and cash equivalents, beginning of period	168.61M
Cash and cash equivalents, end of period	214.09M
Assets acquired through capital leases

Entities mentioned with CHRS

View All Entities